Phase 1 Cardiomyopathy Trial, Recruiting NCT06228924 Sponsor: Tenaya Therapeutics Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 1 Cardiomyopathy Trial, Recruiting

NCT06228924
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a specific gene change (mutation) in the PKP2 gene that is known or likely to cause disease
  • You have been diagnosed with a heart condition called Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), based on specific medical guidelines from 2010
  • Your heart's pumping strength (specifically the left side of your heart) is at 50% or above, meaning it is pumping normally or near-normally
  • You have had a working implantable defibrillator (a device in your chest that can shock your heart back into a normal rhythm) for at least 9 months before the study starts, and it can send data remotely
  • Your heart failure symptoms are mild to moderate — you are in functional class I, II, or III (meaning you can carry out at least some daily activities)
  • You experience frequent irregular heartbeats that start in the lower chambers of your heart (called premature ventricular contractions, or PVCs)

Who may not be able to join:

  • You have had a procedure to treat dangerous heart rhythm problems (ventricular tachycardia ablation) within the last 6 months, or one is planned within the next 6 months
  • You have high levels of a certain antibody in your blood that could interfere with the treatment being studied (confirm with trial site)
  • You have previously had a heart attack
  • You have heart failure specifically affecting the right side of your heart
  • Your heart failure is at the most severe level (Class IV), meaning you have symptoms even at rest
  • You have a serious kidney condition
  • You have a serious liver condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (650) 416-1186

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Tenaya Therapeutics
Registry
ClinicalTrials.gov
Start date
26 March 2024
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number and severity of Adverse Events over the course of the study.; Number of Serious Adverse Events related to study drug.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov